Grösste Beteiligung bis jetzt.
Publikationsdatum 16.05.2015 Emittent Cytos Biotechnology AG Aktionär(e)/Gruppe Abingworth Bioventures V L.P., 38 Jermyn Street, SW1Y 6DN London UK Abingworth Bioequities Master Fund Limited, PO Box 309, Ugland House, KY1-1104 Grand Cayman Cayman Islands Indirekte(r) Halter: Abingworth LLP, 38 Jermyn Street, SW1Y 6DN, London UK Joseph Anderson, Surrey UK Bemerkungen - Shares and warrants are directly held by Abingworth Bioventures V L.P., 38 Jermyn Street, London SW1Y 6DN, which is controlled by Abingworth Bioventures V GP L.P., 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ, as general partner. Abingworth Bioventures V GP L.P, in turn, is controlled by Abingworth General Partner V LLP, 38 Jermyn Street, London SW1Y 6DN, as general partner. Abingworth General Partner V LLP, in turn, is controlled by Abingworth Bioventures V GP Limited, 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ. Abingworth Bioventures V GP Limited, in turn, is controlled by Abingworth LLP, 38 Jermyn Street, London SW1Y 6DN. Certain employee options on shares in the Company are held for the account of Abingworth LLP as the investment manager of Abingworth Bioventures V L.P., by Joseph Anderson, Surrey, UK. - Warrants are directly held by Abingworth Bioequities Master Fund Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Island, which operates as an integrated investment structure. Abingworth Bioequities Master Fund Limited is fed by (i) Abingworth Bioequities Fund Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands, and by (ii) Abingworth Bioequities Fund L.P., 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801, USA. Abingworth Bioequities Fund Limited is managed by Abingworth LLP, 38 Jermyn Street, London SW1Y 6DN, UK. Abingworth Bioequities Fund L.P is controlled by Abingworth Bioequities GP Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands, as general partner. Abingworth Bioequities GP Limited, in turn, is controlled by Abingworth LLP, 38 Jermyn Street, London SW1Y 6DN, UK. Bemerkungen Under common control Papierart Anzahl Rechte Anzahl Stimmrechte Stimmrechtsanteil ISIN / wesentliche Bedingungen / Bemerkungen Erwerbspositionen (Total) 17.07 % Namenaktie 12'659'555 12'659'555 11.72 % Sonstige 30'000 30'000 0.03 % Emittent Cytos Biotechnology AG Bezugsverhältnis 1:1 Ausübungspreis 2.57 Ausübungsfrist 28.09.2018 Ausübungsart Realerfüllung Bemerkungen Employee Options Underlying: Shares of Cytos Biotechnology AG with a par value of CHF 0.03 each Exercise Period: 6 years starting from September 28, 2012 (Grant Date) Adjustment in percentage ownership due to capital increase Listing: Not listed Call-Option/Warrant 5'748'662 5'748'662 5.32 % Emittent Cytos Biotechnology AG Bezugsverhältnis 1:1 Ausübungspreis 2.13 Ausübungsfrist 14.05.2016 Ausübungsart Realerfüllung Bemerkungen Underlying: Shares of Cytos Biotechnology AG with a par value of CHF 0.03 each Exercise Period: 4 years starting from, but excluding, May 14, 2012 (Issuance Date) Adjustment in percentage ownership due to capital increase Listing: Not listed
